Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family

Camilo E. Quevedo, Carole J. R. Bataille, Simon Byrne, Matthew Durbin, Jon Elkins, Abigail Guillermo, Alan M. Jones, Stefan Knapp, Anna Nadali, Roderick G. Walker, Isabel Wilkinson, Graham M. Wynne, Stephen G. Davies, Angela J. Russell

Research output: Contribution to journalArticlepeer-review

Abstract

We have previously reported the discovery of a series of rhodanine-based inhibitors of the PIM family of serine/threonine kinases. Here we described the optimisation of those compounds to improve their physicochemical and ADME properties as well as reducing their off-targets activities against other kinases. Through molecular modeling and systematic structure activity relationship (SAR) studies, advanced molecules with high inhibitory potency, reduced off-target activity and minimal efflux were identified as new pan-PIM inhibitors. One example of an early lead, OX01401, was found to inhibit PIMs with nanomolar potency (15 nM for PIM1), inhibit proliferation of two PIM-expressing leukaemic cancer cell lines, MV4-11 and K562, and to reduce intracellular phosphorylation of a PIM substrate in a concentration dependent manner.
Original languageEnglish
JournalBioorganic & Medicinal Chemistry
DOIs
Publication statusPublished - 15 Nov 2020

Fingerprint

Dive into the research topics of 'Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family'. Together they form a unique fingerprint.

Cite this